Science Explorer Back to mapMap

Most cited papers from Creativ-Ceutical (France)

What are the most cited papers from Creativ-Ceutical (France)?

The most cited paper from Creativ-Ceutical (France) is "Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review" (Rupert Martin Bauersachs, Uwe Zeymer, J Brière et al., 2019), with 451 citations. Next come "Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison" (258) and "Humanistic burden in schizophrenia: A literature review" (246).

Showing 50 of 60 papers. Every paper with more than 36 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review Rupert Martin Bauersachs, Uwe Zeymer, J Brière et al. · Cardiovascular Therapeutics Open access 26 Nov 2019 451
2 Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison Khaled Maman, Samuel Aballéa, Jameel Nazir et al. · European Urology Review 21 Nov 2013 258
3 Humanistic burden in schizophrenia: A literature review A. Millier, Ulrike H Schmidt, Matthias C. Angermeyer et al. · Journal of Psychiatric Research Open access 4 Apr 2014 246
4 Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis Con J. Kelleher, Zalmaï Hakimi, Richard M. Zur et al. · European Urology ReviewOpen access 23 Apr 2018 228
5 Key drivers for market penetration of biosimilars in Europe Cécile Rémuzat, Julie Dorey, Olivier Cristeau et al. · Journal of Market Access & Health Policy Open access 2017 216
6 Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice Christopher Reginald Chapple, Jameel Nazir, Zalmaï Hakimi et al. · European Urology Open access 11 Feb 2017 209
7 Advanced therapy medicinal products: current and future perspectives Eve Hanna, Cécile Rémuzat, Pascal Auquier et al. · Journal of Market Access & Health Policy Open access 2016 169
8 The value of childhood combination vaccines: From beliefs to evidence Khaled Maman, York Francis Zöllner, Donato Greco et al. · Human Vaccines & Immunotherapeutics Open access 15 Jun 2015 160
9 Annual public health and economic benefits of seasonal influenza vaccination: a European estimate Emmanuelle Preaud, Laure Durand, Bérengère Macabeo et al. · BMC Public Health Open access 7 Aug 2014 146
10 Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group Sandra Nestler-Parr, Daria A. Korchagina, Mondher Toumi et al. · Value in Health Open access 11 Apr 2018 143
11 Gene therapies development: slow progress and promising prospect Eve Hanna, Cécile Rémuzat, Pascal Auquier et al. · Journal of Market Access & Health Policy Open access 2017 129
12 Measuring health-related quality of life in young children: how far have we come? Nicola Germain, Samuel Aballéa, Mondher Toumi · Journal of Market Access & Health Policy Open access 2019 127
13 Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA Samuel Aballéa, Florent Guelfucci, R Wagner et al. · Health and Quality of Life Outcomes Open access 2013 122
14 Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries Jesper Jørgensen, Eve Hanna, Panos Kefalas · Journal of Market Access & Health Policy Open access 2020 119
15 Stigma in visible skin diseases – a literature review and development of a conceptual model Nicola Germain, Matthias Augustin, Clément François et al. · Journal of the European Academy of Dermatology and Venereology Open access 15 Jan 2021 115
16 Quality of life is predictive of relapse in schizophrenia Laurent Boyer, A. Millier, Emeline Perthame et al. · BMC Psychiatry Open access 9 Jan 2013 112
17 The real-life impact of vaccination on COVID-19 mortality in Europe and Israel Katarzyna Jabłońska, Samuel Aballéa, Mondher Toumi · Public Health Open access Sep 2021 107
18 Overview of external reference pricing systems in Europe Cécile Rémuzat, Duccio Urbinati, Olfa Mzoughi et al. · Journal of Market Access & Health Policy Open access 2015 106
19 Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study Rimei Nishimura, Haruka Kato, Koichi Kisanuki et al. · BMJ Open Open access Mar 2019 104
20 Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update Ru Han, Junwen Zhou, Clément François et al. · BMC Infectious Diseases ReviewOpen access 23 Jul 2019 75
21 Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France CHRISTOS CHOUAID, Lionel Bensimon, Emilie Clay et al. · Lung Cancer Open access 23 Nov 2018 73
22 Equipercentile linking of scales measuring functioning and symptoms: Examining the GAF, SOFAS, CGI-S, and PANSS Myrto T. Samara, Rolf R. Engel, A. Millier et al. · European Neuropsychopharmacology 20 Aug 2014 70
23 Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting Zalmaï Hakimi, Samuel Aballéa, Sameh Ferchichi et al. · Transplant Infectious Disease Open access 9 Jun 2017 69
24 Cost-effectiveness analyses using real-world data: an overview of the literature Kevin Bowrin, J Brière, Pierre Lévy et al. · Journal of Medical Economics Open access 28 Feb 2019 65
25 Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature Susana Murteira, Zied Ghezaiel, Slim Karray et al. · Journal of Market Access & Health Policy Open access 2013 63
26 Evaluation of the treatment patterns and economic burden of dysmenorrhea in Japanese women, using a claims database Sayako Akiyama, Erika Tanaka, Olivier Cristeau et al. · ClinicoEconomics and Outcomes Research Open access May 2017 62
27 Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey Matthias C. Angermeyer, A. Millier, Cécile Rémuzat et al. · BMC Psychiatry Open access 20 Nov 2013 61
28 Access to orphan drugs in Europe: current and future issues Morgane Michel, Mondher Toumi · Expert Review of Pharmacoeconomics & Outcomes Research 27 Jan 2012 60
29 Supply-side and demand-side policies for biosimilars: an overview in 10 European member states Cécile Rémuzat, Anna Kapusniak, Aleksandra Caban et al. · Journal of Market Access & Health Policy Open access 2017 59
30 Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review Tadao Akizawa, Hiroyuki Okumura, Ana Filipa Alexandre et al. · Therapeutic Apheresis and Dialysis Open access 18 Jul 2018 58
31 Direct healthcare cost of schizophrenia – European overview Gábor László Kovács, Tímea Almási, A. Millier et al. · European Psychiatry Open access 2018 58
32 Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe M. Uhart, Hélène Bricout, Emilie Clay et al. · Human Vaccines & Immunotherapeutics Open access 11 May 2016 58
33 Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors Ayman Chit, Julie Roïz, B. Briquet et al. · Vaccine Open access 11 Nov 2014 58
34 Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts Szymon Jarosławski, Mondher Toumi · BMC Health Services Research Open access 8 Oct 2011 55
35 Funding breakthrough therapies: A systematic review and recommendation Emeline M. Hanna, Mondher Toumi, Claude Dussart et al. · Health Policy Review 2 Dec 2017 53
36 Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data Michel Lantéri‐Minet, Anne Ducros, Clément François et al. · Cephalalgia ReviewOpen access 8 Sep 2022 52
37 Cultural differences in stigma surrounding schizophrenia: Comparison between Central Europe and North Africa Matthias C. Angermeyer, Mauro Giovanni Carta, Herbert Matschinger et al. · The British Journal of Psychiatry Open access 11 Jan 2016 52
38 Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications Susana Murteira, A. Millier, Zied Ghezaiel et al. · Journal of Market Access & Health Policy Open access 2014 51
39 Regenerative medicine regulatory policies: A systematic review and international comparison Tingting Qiu, Eve Hanna, Monique Dabbous et al. · Health Policy ReviewOpen access 24 May 2020 50
40 Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis J.S. Elborn, A.L. Vataire, Ayako Fukushima et al. · Clinical Therapeutics ReviewOpen access Oct 2016 50
41 Development of the Alcohol Quality of Life Scale (AQoLS): a new patient-reported outcome measure to assess health-related quality of life in alcohol use disorder Amandine Luquiens, Diane Whalley, SR Crawford et al. · Quality of Life Research 19 Nov 2014 50
42 An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model Ayman Chit, Julie Roïz, Samuel Aballéa · PLoS ONE Open access 29 Jul 2015 50
43 Comparison of NITAG policies and working processes in selected developed countries Walter Ricciardi, Mondher Toumi, Catherine Weil-Olivier et al. · Vaccine Open access 23 Sep 2014 47
44 Continuum beliefs and attitudes towards people with mental illness: Results from a national survey in France Matthias C. Angermeyer, A. Millier, Cécile Rémuzat et al. · International Journal of Social Psychiatry 24 Jul 2014 46
45 A critical literature review of health economic evaluations of rotavirus vaccination Samuel Aballéa, A. Millier, Sibilia Quilici et al. · Human Vaccines & Immunotherapeutics Open access 29 May 2013 46
46 Family caregiving in dementia and its impact on quality of life and economic burden in Japan-web based survey Ataru Igarashi, Ayako Fukuda, Lida Teng et al. · Journal of Market Access & Health Policy Open access 2020 44
47 Filling the gap in CNS drug development: evaluation of the role of drug repurposing Aleksandra Caban, K. Pisarczyk, Kenneth Kopacz et al. · Journal of Market Access & Health Policy Open access 2017 43
48 Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe Goran Medić, Daria A. Korchagina, Katherine Eve Young et al. · Journal of Market Access & Health Policy Open access 2017 43
49 Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients Francis Shupo, Sophie Dam, Natalia Hawken et al. · Patient Preference and Adherence Open access 2016 42
50 Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan Hironobu Mitani, Kota Suzuki, Junya Ako et al. · Journal of Atherosclerosis and Thrombosis Open access 16 Mar 2023 41

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.